Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Fortress Biotech Stock Jumped Today

By Prosper Junior Bakiny - Dec 17, 2020 at 4:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the company's subsidiaries announced some good news today.

What happened?

Shares of Fortress Biotech ( FBIO -1.41% ) soared on Thursday and closed the day's trading session up by 16.7%. The catalyst for these nice gains was a regulatory update from Avenue Therapeutics ( ATXI 53.15% ), a subsidiary of Fortress Biotech.

So what

Back in October, Avenue Therapeutics received a Complete Response Letter (CDL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for IV tramadol, a medication intended for the management of acute pain in patients who require an opioid. The FDA's concern was that the drug did not seem safe for its intended target market.

However, Avenue Therapeutics did not give up on IV tramadol. Lucy Lu, the company's CEO, stated the following:

We firmly stand behind the safety data in our NDA and the ultimate approvability of IV tramadol. We will request a meeting with the FDA as soon as possible and are committed to working closely with the agency to resolve these issues in order to bring this important medicine to patients and clinicians in the U.S.

Man holding piece of paper that says "FDA Approved."

Image source: Getty Images.

Today, Avenue Therapeutics announced that following a recent meeting with the regulatory agency, it will resubmit an NDA for IV tramadol to the FDA in February 2021, provided there aren't any setbacks related to the ongoing COVID-19 pandemic.

Now what

Avenue Therapeutics has a lot riding on this program since the healthcare company currently does not have any products on the market. The biotech's shares soared by as much as 69.4% today and were up by 48% at the end of the day. Given that Avenue Therapeutics is owned by Fortress Biotech, it isn't surprising to see investors also bid up shares of the latter following this news. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fortress Biotech, Inc. Stock Quote
Fortress Biotech, Inc.
$2.79 (-1.41%) $0.04
Avenue Therapeutics, Inc. Stock Quote
Avenue Therapeutics, Inc.
$1.70 (53.15%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.